A double-blind study reveals that mindfulness meditation practice may amplify the positive effects of psilocybin while reducing the likelihood of a bad trip.
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
The catalog of compounds for use in psychedelic drug research continues to grow.
The researchers hope these compounds “will expand the universe of options for improving mental health.”
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
Three clinical trials are underway to find out if these psychedelic compounds can provide relief for patients.
Surprisingly, 4-HO-TMT has binding affinity similar to psilocin at 5-HT2A.
These creatures have more in common with humans than one might suspect.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.